Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Francisco, California 94143


The purpose of this study is to determine the safety and pharmacokinetics of moderate to high doses of erythropoietin in newborn infants with birth asphyxia.

Study summary:

Newborn infants with birth asphyxia are at high risk of death or long-term neurologic disability; yet therapies for birth asphyxia are currently limited. Erythropoietin (Epo) is a FDA-approved drug that is an effective neuroprotective agent in animal models of birth asphyxia. This is a phase I dose finding multi-center trial that will test the safety and pharmacokinetics of Epo in human infants with birth asphyxia. The long-term objectives of the proposed research are to reduce mortality and to decrease the risk of long-term disabilities in infants who survive beyond the newborn period.


Inclusion Criteria: 1. ≥ 36 weeks gestational age 2. Perinatal depression (low Apgar score, need for resuscitation) 3. Moderate to severe encephalopathy Exclusion Criteria: 1. Specific aEEG findings 2. Intrauterine growth restriction 3. Severe congenital anomaly, genetic syndrome, metabolic disorder, arthrogryposis, TORCH infection 4. Microcephaly 5. Infant older than 23.5 hours of age at the time of consent 6. Infant judged by an attending physician to be likely to die due to the severity of illness 7. Polycythemia 8. Hypertension 9. No in-dwelling line



Primary Contact:

Principal Investigator
Yvonne W Wu, MD, MPH
University of California, San Francisco

Backup Contact:


Location Contact:

San Francisco, California 94143
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.